Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?

Danesi, R; Del Re, M; Ciccolini, J; Schellens, J H M; Schwab, M; van Schaik, R H N; van Kuilenburg, A B P

Danesi, R; Del Re, M; Ciccolini, J; Schellens, J H M; Schwab, M; van Schaik, R H N; van Kuilenburg, A B P.

Afiliación

Danesi R; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Del Re M; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Ciccolini J; Clinical Pharmacokinetics, La Timone University Hospital, Marseille, and GPCO-Unicancer, Paris, France.
Schellens JHM; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Schwab M; Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany.
van Schaik RHN; IFCC Reference center - Pharmacogenetics, Department of Clinical Chemistry, Erasmus University, Rotterdam.
van Kuilenburg ABP; Department of Clinical Chemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Ann Oncol ; 28(1): 183, 2017 01 01.

Article en En | MEDLINE | ID: mdl-27687313

Asunto(s)

Dihidrouracilo Deshidrogenasa (NADP); Fluorouracilo; Hipersensibilidad a las Drogas; Humanos; Pirimidinas

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Dihidrouracilo Deshidrogenasa (NADP) / Fluorouracilo Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google